Kurzfassung

An open-labeled, randomized, two-dose, parallel group trial of Ofatumumab, a fully human monoclonal anti-CD20 antibody, in combination with Fludarabine and Cyclophosphamide, in patients with previously untreated B-cell Chronic Lymphocytic Leukemia